Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
复制标题
DOI：
10.1016/j.ctarc.2020.100164
复制
发表时间：
2020-01-07
影响因子：
--
通讯作者：
Antonarakis, Emmanuel S
中科院分区：
文献类型：
--
作者：
Marshall, Catherine Handy;Antonarakis, Emmanuel S
最近，研究用于治疗前列腺癌的新药物激增。这些模式代表了针对旧靶点的新疗法和针对新靶点的新疗法。本综述将突出三个新的和新兴的治疗领域，这些领域有可能在不久的将来显著影响转移性去势抵抗性前列腺癌（mCRPC）的管理：免疫治疗，聚ADP-核糖聚合酶（PARP）抑制剂和前列腺特异性膜抗原（PSMA）靶向模式。免疫治疗，特别是免疫检查点阻断剂，PARP抑制剂和PSMA靶向治疗都越来越多地被研究用于治疗mCRPC，尽管目前没有FDA批准专门用于前列腺癌。这三类治疗可能会彻底改变mCRPC的未来前景。本综述将涵盖目前已知的这些药物用于治疗mCRPC的效用，积极研究的领域，以及这些药物将来如何对患者有用。它还将强调生物标志物选择的概念，以帮助告知哪些患者更有可能对这些疗法作出反应。
Recently there has been an explosion of new agents being investigated for the treatment of prostate cancer. These modalities represent new therapies aimed at old targets, and new therapies addressing new targets. This review will highlight three novel and emerging areas of treatment that have the potential to significantly impact the management of metastatic castration-resistant prostate cancer (mCRPC) in the near future: immunotherapy, poly ADP-ribose polymerase (PARP) inhibitors, and prostate-specific membrane antigen (PSMA)-targeted modalities. Immunotherapy, particularly immune checkpoint blockers, PARP inhibitors, and PSMA-targeted therapies are all increasingly being studied for the treatment of mCRPC although none are currently FDA-approved specifically for prostate cancer. Together these three classes of treatments may drastically change the future landscape of mCRPC. This review will cover what is currently known about the utility of these agents for the treatment of mCRPC, the areas of active research, and how these agents may be useful for patients in the future. It will also emphasize the notion of biomarker selection to help inform which patients are more likely to respond to these therapies.